We applied the miRCURY LNA microarray platform to generate miRNA expression profiles of breast cancer tissue and normal adjacent breast tissue to identify possible new biomarkers for breast cancer 9.
Unlike expensive, invasive and risky tissue biopsies, the biomarkers found in body fluids, such as blood, urine or cerebral spinal fluid, offer an easier way to spot the first signs of cancer or ...
The US$40 million synthetic royalty-backed financing provided by R-Bridge is long-term with flexible and customized repayment schedule to meet Mirxes' near-term strategic priorities. Proceeds from the ...
A new University of Cincinnati Cancer Center study has identified a particular strand of microRNA as a promising new target for overcoming breast cancer treatment resistance and improving outcomes.
Mirxes, a leading Singapore-based cancer detection firm, has secured $40 million in financing from CBC Group's R-Bridge Fund to enhance its innovative miRNA technology platform. The investment aims to ...
A multi-institutional team of scientists has developed a free, publicly accessible resource to aid in classification of patient tumor samples based on distinct molecular features identified by The ...
Particularly microRNAs have emerged as informative biomarkers of cell status and function. Sensitive, specific and unbiased microRNA profiling in liquid biopsies – from serum and plasma, to urine and ...